Activation of the androgen receptor (AR) and AR-driven transcriptional programs is central to
the pathophysiology of prostate cancer. Despite successful translational efforts in targeting …

Owing to the development of multiple novel therapies, there has been major progress in the
treatment of advanced prostate cancer over the last two decades; however, the disease …

Huggins and Hodges demonstrated the therapeutic effect of gonadal testosterone
deprivation in the 1940s and therefore firmly established the concept that prostate cancer is …

Background Although germline BRCA mutations have been associated with adverse
outcomes in prostate cancer (PC), understanding of the association between …

Prostate cancer is highly dependent on androgens and the androgen receptor (AR).
Hormonal therapies inhibit gonadal testosterone production, block extragonadal androgen …

BACKGROUND Metastatic hormone-sensitive prostate cancer (mHSPC) is androgen
dependent, and its treatment includes androgen deprivation therapy (ADT) with gonadal …

Importance The adrenal androgen–metabolizing 3β-hydroxysteroid dehydrogenase-1
enzyme, encoded by theHSD3B1gene, catalyzes the rate-limiting step necessary for …

Androgens play an essential role in prostate cancer. Clinical treatments that target
steroidogenesis and the androgen receptor (AR) successfully postpone disease …

Prostate cancer continuously progresses following deprivation of circulating androgens
originating from the testis and adrenal glands, indicating the existence of oncometabolites …

Novel strategies for prostate cancer therapy are required to overcome resistance to
abiraterone and enzalutamide. Here, we show that increasing 3βHSD1 after abiraterone …